- The 8 States Most Likely to Legalize Marijuana Next
- BlackBerry Is Finally Realizing Smartphones Aren't the Answer
- Express Scripts and AbbVie Drug-Pricing Deal Might Devastate Biotech Bull Market
- Dow 18,000: Why This Market Rally May Never Happen Again
- Gilead Sciences Is Not a Buy; It's Heading Lower on Price War: Jim Cramer
We're taking some profits in two holdings and padding another position. Plus, an update on one tech holding.
The market is still under distribution, but rallies usually begin when things look the worst.
A 2% gain on the Nasdaq with higher volume than the prior session would signal it's time to nibble.
The recent technical damage done to the major averages will take more time to repair.
As fears of a double-dip recession mount, so does the appetite for these precious metals.
The company anticipates lower benefit-expense ratios at its retail and employer group businesses.
Analysts expect the company to report earnings of $2.06 per share on $9.3 billion in sales.
Medical software companies are thriving and could be bought in a better market.
Some stocks hung in there, while others suffered notable technical breakdowns.
Management expressed caution for the second-half 2011, but is optimistic about 2012.